Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -9.76% is 67% above its 5-year average of -29.68%, near the high end of its 5-year range (-72.00%–2.17%).
64.72% below its 12-month average of -5.93%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5.58%.
EBITDA MARGIN
-9.76%
EBITDA MARGIN AVG TTM
-5.93%
EBITDA MARGIN AVG 3Y
-16.00%
EBITDA MARGIN AVG 5Y
-29.68%
EBITDA MARGIN AVG 10Y
-34.81%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-64.72%
CURRENT VS 3Y AVG
+39.01%
CURRENT VS 5Y AVG
+67.12%
CURRENT VS 10Y AVG
+71.96%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SI-BONE, Inc.
Market Cap
$867.03M
EBITDA Margin
-9.76%
TTM Avg
-5.93%
3Y Avg
-16.00%
5Y Avg
-29.68%
Market Cap
$870.81M
EBITDA Margin
-5250.17%
TTM Avg
-5250.17%
3Y Avg
-5250.17%
5Y Avg
-5250.17%
Market Cap
$857.16M
EBITDA Margin
-17.48%
TTM Avg
-35.83%
3Y Avg
-4.31%
5Y Avg
17.66%
Market Cap
$855.38M
EBITDA Margin
-1761.78%
TTM Avg
-1761.78%
3Y Avg
-1761.78%
5Y Avg
-1761.78%
Market Cap
$853.13M
EBITDA Margin
43.46%
TTM Avg
29.10%
3Y Avg
-0.91%
5Y Avg
-6.21%
Market Cap
$852.35M
EBITDA Margin
-170.39%
TTM Avg
-102.27%
3Y Avg
-63.10%
5Y Avg
-63.10%
Market Cap
$884.97M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$887.99M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $867.03M | -9.76% | -5.93% | -16.00% | -29.68% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | -5250.17% | -5250.17% | -5250.17% | -5250.17% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -17.48% | -35.83% | -4.31% | 17.66% |
| Alumis Inc. (ALMS)vs › | $855.38M | -1761.78% | -1761.78% | -1761.78% | -1761.78% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 43.46% | 29.10% | -0.91% | -6.21% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -170.39% | -102.27% | -63.10% | -63.10% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | -189.51% | -701.94% | -497.69% | -575.23% |
| Bioventus Inc. (BVS)vs › | $887.50M | 18.58% | 12.56% | -0.37% | 4.16% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -32.91% | -153.12% | -170.67% | -159.26% |
Gross Margin
79.5%
EBITDA Margin
-9.8%
Operating Margin
-8.3%
Net Margin
-6.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5.58% |
| 2026-03-31 | -6.61% |
| 2025-12-31 | 2.17% |
| 2025-09-30 | -8.01% |
| 2025-06-30 | -11.59% |
| 2025-03-31 | -13.11% |
| 2024-12-31 | -8.74% |
| 2024-09-30 | -16.23% |
| 2024-06-30 | -22.73% |
| 2024-03-31 | -28.93% |
| 2023-12-31 | -28.14% |
| 2023-09-30 | -28.33% |
| 2023-06-30 | -32.21% |
| 2023-03-31 | -31.21% |
| 2022-12-31 | -32.21% |
| 2022-09-30 | -47.75% |
| 2022-06-30 | -66.79% |
| 2022-03-31 | -72.00% |
| 2021-12-31 | -52.64% |
| 2021-09-30 | -56.57% |
| 2021-06-30 | -56.14% |
| 2021-03-31 | -54.96% |
| 2020-12-31 | -33.99% |
| 2020-09-30 | -41.20% |
| 2020-06-30 | -70.35% |
| 2020-03-31 | -69.16% |
| 2019-12-31 | -41.80% |
| 2019-09-30 | -64.31% |
| 2019-06-30 | -48.64% |
| 2019-03-31 | -57.41% |
| 2018-12-31 | -26.38% |
| 2018-09-30 | -21.40% |
| 2018-06-30 | -11.04% |
| 2018-03-31 | -21.63% |
| 2017-12-31 | -10.49% |
| 2017-09-30 | -40.98% |
| 2017-06-30 | -39.58% |
| 2017-03-31 | -46.14% |
| 2016-03-31 | -65.19% |
| 2015-03-31 | -64.74% |
| 2014-12-31 | -71.72% |
| 2014-03-31 | -33.08% |
